Loading data for ANRO — first visit, this takes a few seconds.

Preisalarm

Alto Neuroscience Inc. (ANRO)

NYSE: ANRO · Echtzeitkurs · USD

34.26

+0.13 (0.38%)

Zum Schluss: Aug 18, 2026, 8:00 PM

0.38% (1D)

Keine Daten verfügbar

Geld	34.16
Marktkapitalisierung	1.34 Mrd
Umsatz (TTM)	n/a
Nettogewinn (TTM)	-84.24 Mio
Beta	1.09
EPS (ttm)	-2.32
KGV (TTM)	n/a
Forward-KGV	-10.39
KBV (TTM)	5.46
KUV (TTM)	n/a
Earnings Date	Nov 11, 2026

Brief	34.43
Volumen	129,759
Ø Vol. (20D)	521,974
Eröffnung	35.00
Vortagesschluss	34.13
Tagesspanne	33.80 - 35.34
52-Wk Range	3.32 - 35.34
Analyst	n/a
Kursziel	n/a
Dividenden	n/a
Ex-Dividenden-Datum	n/a

Über ANRO

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive d...

[Mehr lesen]

Branche Biotechnology

Sektor Healthcare

IPO Datum Feb 2, 2024

Mitarbeiter 68

Börse NYSE

Tickersymbol ANRO

Website https://www.altoneuroscience.com

Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von Alto Neuroscience 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -63.24 Mio, ein Anstieg von 2.94 %.

Finanzberichte

Gewinnüberraschung

Alto Neuroscience hat die Quartalszahlen am Aug 12, 2026 veröffentlicht:

Umsatz von $0 verfehlt die Erwartungen um $0, mit NaN% Wachstum im Jahresvergleich.

EPS von -0.65 übertrifft die Erwartungen um 0.12, mit 0.00% Wachstum im Jahresvergleich.

Nächste Ergebnisveröffentlichung

Alto Neuroscience Inc. wird voraussichtlich die Quartalszahlen veröffentlichen am Nov 11, 2026, während der Handelszeiten.
Analysten erwarten einen Umsatz von ... Upgrade

Nachrichten

vor 2 Tagen · Simply Wall St.

Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued?

Alto Neuroscience (ANRO) is back in focus after reporting second quarter 2026 results. The company reported a net loss of US$27.64 million and a basic loss per share from continuing operations of US$0...

vor 3 Tagen · Simply Wall St.

Are Alto Neuroscience’s (ANRO) Rising Losses Funding a Stronger Depression Pipeline or Diluting Discipline?

Alto Neuroscience, Inc. reported its second-quarter and first-half 2026 results, recording a wider net loss of US$27.64 million for Q2 and US$53.88 million for the six months ended June 30, 2026, with...

vor 3 Tagen · Simply Wall St.

Alto Neuroscience (ANRO) Stock Looks Stretched On Expanded ALTO 207 Plans

Alto Neuroscience stock has delivered a very large gain over the past year, yet the valuation checks currently lean toward the shares looking expensive rather than like a clear bargain. Over the last ...

vor 1 Monat · Insider Monkey

Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment?

We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. Alto Neuroscience, Inc. (NYSE:ANRO) is one of the best up and coming stocks on our list. On June 15, ALTO high...

vor 2 Monaten · Motley Fool

Alpha Wave Global Initiates COPT Defense Properties Position, According to Recent SEC Filing

COPT Defense Properties serves defense and intelligence tenants near secure government hubs. Investors will be closely watching whether that niche can keep supporting growth while much of the office m...

Seite 1 von 2

Alto Neuroscience Inc. (ANRO)